This nonrandomized, noncontrolled clinical trial evaluates the 6-month progression-free survival, tumor objective response, and overall survival rates in patients with gastrointestinal stromal tumors treated with dasatinib.
from Cancer via ola Kala on Inoreader https://ift.tt/2FhgVXy
via IFTTT
Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου